Comparison between external beam radiotherapy (70Gy/74Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients

Goldner, Gregor; Pötter, Richard; Battermann, Jan J.; Kirisits, Christian; Schmid, Maximilian; Sljivic, Samir; Vulpen, Marco van

doi:10.1016/j.radonc.2012.01.016

Cited by 15 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, this increased risk of metastasis has not resulted in observable differences in OS or PC-specific mortality, but the conclusions of the study could change with additional follow-up. As a whole, the results in LR patients undergoing AS are consistent with those from randomized trials showing no OS benefit to RP 8 , 9 ; EBRT +ADT 41 has been included in national guidelines, 19 which may explain the increased utilization of NDT seen in our study.…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database

Burt

Shrieve

Tward

2018

Advances in Radiation Oncology

View full text Add to dashboard Cite

PurposeThe aim of this study is to describe the trends and factors that influence the initial treatment of men with localized prostate cancer (PC) in the United States between 2004 and 2014.Methods and materialsThe National Cancer Institute's Surveillance, Epidemiology and End Results database was used to identify patients with primary prostate adenocarcinoma between 2004 and 2014. Patients were staged in accordance with the American Joint Committee on Cancer 7th edition criteria and stratified according to the National Comprehensive Cancer Network guidelines risk group classification. Descriptive statistics describing treatment patterns by year of diagnosis, age, risk group, insurance status, and region were performed.ResultsA total of 460,311 male patients were identified with sufficient information to be categorized into National Comprehensive Cancer Network risk groups. Overall, 30.9% of patients had low-risk disease, 38.1% were intermediate risk, 20.2% were high risk, 4.4% were very high risk, 1.6% were node-positive, and 4.7% had metastatic disease. During the study period, there was a 60% decrease in brachytherapy monotherapy utilization for patients with PC, and no definitive treatment increased from 20.3% in 2004 to 26.3% in 2014. There were regional treatment variations and discrepancies in treatment by age. Radical prostatectomy was performed on a greater proportion of insured patients than patients with Medicaid or those who were uninsured, but radiation therapy and no definitive treatment was administered to a greater proportion of uninsured and Medicaid patients.ConclusionsPC treatment shows declining trends in brachytherapy utilization, increases in conservative management, and stability of surgical procedures over time. There is wide variation by geographical region, age, and insurance status.

show abstract

Section: Discussionsupporting

confidence: 85%

“… 17 , 18 In the IR group, there is no consensus on BM. Studies have shown mixed results with the use of BM, 2 , 15 , 16 , 19 , 20 and the current national guidelines recommend BM for select groups of IR patients. 17 , 20 …”

Section: Discussionmentioning

confidence: 99%

Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database

Burt

Shrieve

Tward

2018

Advances in Radiation Oncology

View full text Add to dashboard Cite

show abstract

“…In a Japanese study involving 663 patients with low-risk and low-tier intermediate-risk confined disease, The 7-year cause-specific survival and overall survival (OS) were 99.1% and 96.4% and there were no significant difference between different risk groups. 105 In addition, the result was excellent compared to data from other studies (5-year biochemical disease-free survival-rates = 81% from Austria, 106 10-year biochemical disease-free survival rate was 83% for Caucasians 107 ). On the other hand, brachytherapy for high-risk Asian patients also had favorable results.…”

Section: Treatmentsupporting

confidence: 54%

Prostate cancer in East Asia: evolving trend over the last decade

Zhu

Wang

et al. 2015

Asian J Androl

View full text Add to dashboard Cite

Prostate cancer is now becoming an emerging health priority in East Asia. Most of our current knowledge on Prostate cancer has been generated from studies conducted in Western population; however, there is considerable heterogeneity of Prostate cancer between East and West. In this article, we reviewed epidemiologic trends, risk factors, disease characteristics and management of Prostate cancer in East Asian population over the last decade. Growing evidence from East Asia suggests an important role of genetic and environmental risk factors interactions in the carcinogenesis of Prostate cancer. Exposure to westernized diet and life style and improvement in health care in combination contribute substantially to the increasing epidemic in this region. Diagnostic and treatment guidelines in East Asia are largely based on Western knowledge. Although there is a remarkable improvement in the outcome over the last decade, ample evidence suggests an inneglectable difference in diagnostic accuracy, treatment efficacy and adverse events between different populations. The knowledge from western countries should be calibrated in the Asian setting to provide a better race-based treatment approach. In this review, we intend to reveal the evolving trend of Prostate cancer in the last decade, in order to gain evidence to improve Prostate cancer prevention and control in East Asia.

show abstract

“…There was no difference in outcome demonstrated for the BT group and EBRT treated to 74 Gy regardless of the number of risk factors. [52]. Vassil et al [16] reported 5-year bNED for IR disease treated with radical prostatectomy, EBRT or BT within a single institution.…”

Section: Discussionmentioning

confidence: 99%

Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy

Tran

Mandall

Swindell

et al. 2013

Radiotherapy and Oncology

View full text Add to dashboard Cite

Comparison between external beam radiotherapy (70Gy/74Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients

Cited by 15 publications

References 31 publications

Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database

Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database

Prostate cancer in East Asia: evolving trend over the last decade

Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy

Contact Info

Product

Resources

About